Analysts take a look at Concordia International Corp. (TSE:CXR) having this to say.

January 14, 2018 - By Peter Erickson

 Analysts take a look at Concordia International Corp. (TSE:CXR) having this to say.

Concordia International Corp. (TSE:CXR) Ratings Coverage

Among 4 analysts covering Concordia Healthcare Corp (TSE:CXR), 0 have Buy rating, 3 Sell and 1 Hold. Therefore 0 are positive. Concordia Healthcare Corp had 34 analyst reports since August 11, 2015 according to SRatingsIntel. As per Tuesday, October 11, the company rating was maintained by RBC Capital Markets. The firm earned “Outperform” rating on Monday, June 20 by RBC Capital Markets. On Friday, July 22 the stock rating was maintained by Goldman Sachs with “”. The stock of Concordia International Corp. (TSE:CXR) earned “Outperform” rating by RBC Capital Markets on Monday, October 17. RBC Capital Markets maintained the shares of CXR in report on Monday, May 16 with “Outperform” rating. The stock of Concordia International Corp. (TSE:CXR) has “Underperform” rating given on Wednesday, January 4 by Scotia Capital. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, October 24. Scotia Capital downgraded Concordia International Corp. (TSE:CXR) rating on Thursday, December 8. Scotia Capital has “Underperform” rating and $0.50 target. The firm has “Hold” rating given on Thursday, December 3 by Mackie. Scotia Capital maintained the shares of CXR in report on Wednesday, September 9 with “Sector Outperform” rating. Below is a list of Concordia International Corp. (TSE:CXR) latest ratings and price target changes.

The stock decreased 3.41% or $0.03 during the last trading session, reaching $0.85. About 183,502 shares traded. Concordia International Corp. (TSE:CXR) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $43.59 million. It operates through three divisions: Concordia International, Concordia North America, and Orphan Drugs. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

More notable recent Concordia International Corp. (TSE:CXR) news were published by: Prnewswire.com which released: “Concordia Healthcare Corp. Announces Name Change to Concordia International …” on June 28, 2016, also Business.Financialpost.com with their article: “Concordia International Corp shares plunge as it seeks to restructure its debts” published on October 20, 2017, Reuters.com published: “BRIEF-Concordia International seeks to realign capital structure under CBCA” on October 20, 2017. More interesting news about Concordia International Corp. (TSE:CXR) were released by: Marketwatch.com and their article: “Concordia International Corp.” published on July 01, 2015 as well as Seekingalpha.com‘s news article titled: “Concordia International Is A Sewer” with publication date: July 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: